The FDA announced on March 2, 2023, that Endo Pharmaceuticals, Inc. is recalling Calcitonin Salmon Nasal Spray due to failed impurity specifications and subpotent drug issues. The agency classified the recall as Class II.
How to tell if you have it
- Brand: Endo Pharmaceuticals
- Product: Calcitonin Salmon Nasal Spray, USP
- Strength: 2200 International Units per mL corresponding to 200 International Units/spray
- Size: 3.7 mL bottle
- NDC: 49884-161-11
- Lot codes and expiration dates: 34770301 (Mar-23), 34770401 (May-23), 12981201 (Nov-23), 13037201 (Dec-23), 13037301 and 13647801 (Feb-24), 13722101 (Mar-24), 13980101 and 13980001 (Apr-24), 14461701 and 14461801 (Jul-24), 14706201 (Aug-24), 14935601 (Oct-24), 5500131A and 5500132A (Mar-25)
- Quantity: 372,938 bottles
- Distribution: Nationwide in the USA and Puerto Rico
The hazard
According to the FDA, the recalled Calcitonin Salmon Nasal Spray has high out-of-specification results for known and unknown impurities as well as low out-of-specification results for assay. This constitutes a failed impurity/degradation specification and subpotent drug hazard.
Context
GovInfoNow's records show Endo Pharmaceuticals, Inc. has four other recalls on record since May 7, 2012. Other recent recalls of similar products include Endo Clonazepam Tablets Recalled Due to Labeling Error (July 10, 2024), Endo Robaxin 750mg Tablets: Incorrect Dosage Label Recall (Sept. 17, 2018), and Endo Edex 10mcg injection recall (Feb. 22, 2017). Other recent recalls of similar products include Sun Pharmaceutical Fluocinolone Acetonide Solution Recall (Dec. 30, 2025) and SUN PHARMA Ciclopirox Shampoo 1% Recall (Dec. 9, 2025).